On May 16, Pfizer (NYSE: PFE) announced that it was going to take out $31 billion in fresh debt to pay for its purchase of Seagen (NASDAQ: SGEN), an oncology drug developer. In total, it'll pay $43 billion for the company in a transaction that's set to reshape its future, and power shareholder returns for the remainder of the 2020s and perhaps beyond.

Somewhat counterintuitively, investors should interpret this debt issuance as good news for Pfizer's stock. Here's why.

Image source: Getty Images.

Continue reading

Source Fool.com